Danish biotechnology company at Søborg near Copenhagen, founded in 1998 and listed in Copenhagen and on Nasdaq, which specialises in peptide medicines. Uses its own peptide chemistry platform to design analogues of gut and metabolic hormones, with dasiglucagon approved for severe hypoglycaemia, glepaglutide for short bowel syndrome, the amylin analogue petrelintide and the glucagon and GLP-1 co-agonist survodutide partnered with Boehringer Ingelheim for obesity, and it licenses programmes to larger pharmaceutical companies.
コメントはありません。
評価とコメントを残す